Prospective Multicenter Observational Study of Overt Hepatic Encephalopathy

• Published in: Digestive diseases and sciences Vol. 61; no. 6; pp. 1728 - 1734
• Main Authors: Landis, C. S., Ghabril, M., Rustgi, V., Di Bisceglie, A. M., Maliakkal, B., Rockey, D. C., Vierling, J. M., Bajaj, J., Rowell, R., Santoro, M., Enriquez, A., Jurek, M., Mokhtarani, M., Coakley, D. F., Scharschmidt, B. F.
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.06.2016; Springer; Springer Nature B.V
• Subjects: Adult; Aged; Aged, 80 and over; Biochemistry; Gastroenterology; Hepatic encephalopathy; Hepatic Encephalopathy - pathology; Hepatology; Humans; Liver Cirrhosis - complications; Medical research; Medicine; Medicine & Public Health; Medicine, Experimental; Middle Aged; Oncology; Original Article; Pneumoviridae; Rifamycins - administration & dosage; Rifamycins - pharmacology; Rifaximin; Transplant Surgery; Tremor; Young Adult; Cirrhosis; Liver failure; Altered mental status; Pharmacoeconomics; Clinical trial; Chronic liver disease; Health-care burden
• ISSN: 0163-2116; 1573-2568
• DOI: 10.1007/s10620-016-4031-7

Background Overt hepatic encephalopathy (OHE) is a frequent complication of decompensated cirrhosis. Aims A multicenter prospective observational study was performed to assess the most commonly recorded presenting manifestations of OHE and its associated health-care burden. Methods Qualifying patients must have experienced ≥1 OHE episode within 30 days of enrollment (qualifying OHE) and were followed for recurrence (on-study OHE). Results Two hundred and sixty-five patients were enrolled at 30 sites and followed for up to 9 months (mean 72 days). Seventy-two patients experienced 122 on-study episodes; with 72, 23, and 13 having ≥1, ≥2, or ≥3 on-study episodes with median days to occurrence of the 1st, 2nd, and 3rd episode of 34, 19, and 11, respectively. The most frequently recorded OHE manifestations included confusion (78 %), change in mental status (57 %), disorientation (48 %), lethargy (46 %), and asterixis (45 %). West Haven grade was used inconsistently and recorded for only 28 % of episodes. Most qualifying and on-study episodes occurred on rifaximin (60 and 82 %, respectively) and were associated with hospitalization (68 and 85 %, respectively). Twenty-three patients experienced ≥2 on-study episodes within 2 months of enrollment on average (median 45 days) and accounted for 60 % of on-study episodes. Conclusions In this prospective study, OHE’s most commonly recorded presenting manifestations included confusion, altered mental status, disorientation, lethargy, and asterixis. As reflected by frequent recurrence and hospitalizations, OHE, particularly the approximately 10 % of “high-resource-utilizing” patients with frequent recurrence, continues to pose a major unmet medical need and health-care burden despite the use of rifaximin.